CUE
Cue Biopharma, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Neutral
+5/100
Last price
22.89
▼ 0.25 (1.08%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
23.50
Prev close
23.14
Day high
23.09
Day low
22.45
Volume
51.45K
Market cap
$166.28M
P/E (TTM)
—
52W range
4.98 – 45.50
Day trading desk
Gap from prior close
+1.56%
Prior close 23.14
VWAP
22.69
+0.90% from price
Relative volume
0.19×
Quiet session
Session range
4.68%
22.45 – 23.50
Position in range
42%
Mid range
ATR (14D)
4.43
19.34% of price
Prior day high
24.89
PDH
Prior day low
22.92
PDL
Bid / ask spread
—
Quote not published
Session volume
50.28K
Avg 268.50K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-11.52%
-13.1%
1M
-23.70%
-24.8%
3M
-37.30%
-40.4%
6M
+178.47%
+163.9%
YTD
+150.16%
+136.6%
1Y
+4.81%
-10.5%
3Y
-63.75%
-145.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on CUE open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+3.45M
Net buying
Buy transactions
75
3.76M shares
Sell transactions
20
314.25K shares
Net transactions
+95
Buys less sells
Sell : buy shares
0.1 : 1
Mixed
Insider-held shares
685.54K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 13, 26 | RAY SUMITA J.D. Officer |
SELL | 8.83K | $265.63K | Direct |
| Aug 13, 26 | RAY SUMITA J.D. Officer |
— | 18.20K | — | Direct |
| Aug 13, 26 | LIN SHAO-LEE Chief Executive Officer |
SELL | 58.26K | $1.61M | Direct |
| Aug 13, 26 | MELUZIO MICHAEL VINCENT CPA Officer |
SELL | 5.63K | $169.32K | Direct |
| Aug 13, 26 | MELUZIO MICHAEL VINCENT CPA Officer |
— | 13.65K | — | Direct |
| Aug 12, 26 | LIN SHAO-LEE Chief Executive Officer |
— | 109.18K | — | Direct |
| Jul 30, 26 | AHLERS JAMES M. Chief Financial Officer |
STOCK | 25.50K | $0 | Direct |
| Jul 13, 26 | BORIE DOMINIQUE CHRISTIAN M.D., PH.D. Officer |
STOCK | 31.50K | $0 | Direct |
| Jul 9, 26 | RAY SUMITA J.D. Officer |
STOCK | 54.59K | $0 | Direct |
| Jul 9, 26 | LIN SHAO-LEE Chief Executive Officer |
STOCK | 327.54K | $0 | Direct |
| Jul 9, 26 | CAMARDO DANIEL A. Director |
STOCK | 21.80K | $0 | Direct |
| Jul 9, 26 | GARZONE PAMELA Director |
STOCK | 21.80K | $0 | Direct |
| Jul 9, 26 | GARZONE PAMELA Director |
STOCK | 18.90K | $0 | Direct |
| Jul 9, 26 | SARRAF PASHA Director |
STOCK | 21.80K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
AHLERS JAMES M. |
Chief Financial Officer | 25.50K | Stock Award(Grant) |
BORIE DOMINIQUE CHRISTIAN M.D., PH.D. |
Officer | 31.50K | Stock Award(Grant) |
CAMARDO DANIEL A. |
Director | 21.80K | Stock Award(Grant) |
GARZONE PAMELA |
Director | 21.80K | Stock Award(Grant) |
LIN SHAO-LEE |
Chief Executive Officer | 706.00K | Sale |
MEEHAN VIOLA MONG |
Director | 21.80K | Stock Award(Grant) |
MELUZIO MICHAEL VINCENT CPA |
Officer | 48.96K | Sale |
PASSERI DANIEL R |
Chief Executive Officer | 164.58K | Purchase |
RAY SUMITA J.D. |
Officer | 118.55K | Sale |
SARRAF PASHA |
Director | 32.59K | Stock Award(Grant) |
Fundamentals
Market cap$166.28M
Enterprise value$153.76M
Revenue (TTM)$37.66M
Gross profit$-37.34M
EBITDA$-97.28M
Net income$-164.11M
EPS (TTM)$-29.59
Free cash flow$-33.43M
Total cash$17.41M
Total debt$3.08M
Book value / share$0.44
Shares outstanding7.26M
Float6.85M
Short % of float4.80%
Dividend yield0.00%
Beta (5Y)2.63
Valuation & profitability ratios
Trailing P/E—
Forward P/E-47.69
PEG ratio—
Price / sales—
Price / book51.79
EV / revenue4.08
EV / EBITDA-1.58
Gross margin-99.15%
Operating margin-1113.31%
Profit margin0.00%
Return on equity-1603.48%
Return on assets-172.66%
Debt / equity133.20
Current ratio1.26
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $27.47M | $9.29M | $5.49M | $1.25M | — | +195.7% |
| Operating revenue | $27.47M | $9.29M | $5.49M | $1.25M | — | +195.7% |
| Research & development | $37.74M | $36.30M | $40.80M | $38.58M | — | +4.0% |
| Selling, general & admin | $16.24M | $14.59M | $16.68M | $16.17M | — | +11.4% |
| Total operating expense | $53.99M | $50.88M | $57.48M | $54.75M | — | +6.1% |
| Operating income | -$26.52M | -$41.59M | -$51.99M | -$53.50M | — | +36.2% |
| Net interest income | $450.00K | $826.00K | $1.42M | $215.00K | — | -45.5% |
| Pre-tax income | -$26.10M | -$40.67M | -$50.73M | -$53.01M | — | +35.8% |
| Tax provision | $500.00K | $0 | — | $0 | $495.00K | — |
| Net income | -$26.60M | -$40.67M | -$50.73M | -$53.01M | — | +34.6% |
| Net income to common | -$26.60M | -$40.67M | -$50.73M | -$53.01M | — | +34.6% |
| Basic EPS | -8.40 | -21.60 | -33.30 | -44.70 | — | +61.1% |
| Diluted EPS | -8.40 | -21.60 | -33.30 | -44.70 | — | +61.1% |
| EBIT | -$25.75M | -$39.88M | -$49.49M | -$52.30M | — | +35.4% |
| EBITDA | -$22.27M | -$37.53M | -$46.05M | -$50.49M | — | +40.7% |
| Basic shares | 3.16M | 1.88M | 1.53M | 1.19M | — | +68.2% |
| Diluted shares | 3.16M | 1.88M | 1.53M | 1.19M | — | +68.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $27.14M | $22.46M | $48.51M | $51.61M | +20.8% |
| Cash & short-term investments | $27.14M | $22.46M | $48.51M | $76.29M | +20.8% |
| Accounts receivable | $5.55M | $945.00K | $1.70M | $57.00K | +486.9% |
| Total current assets | $36.98M | $25.14M | $51.45M | $77.19M | +47.1% |
| Property, plant & equipment | $4.32M | $4.84M | $7.12M | $10.70M | -10.9% |
| Total assets | $42.21M | $32.19M | $61.53M | $91.28M | +31.1% |
| Total current liabilities | $13.49M | $13.69M | $17.08M | $11.55M | -1.4% |
| Current debt | — | $4.33M | $3.96M | $1.96M | — |
| Long-term debt | — | — | $4.20M | $8.04M | — |
| Total debt | $4.20M | $8.88M | $14.70M | $19.32M | -52.7% |
| Total liabilities | $15.78M | $14.69M | $24.45M | $25.60M | +7.4% |
| Retained earnings | -$368.47M | -$341.86M | -$301.19M | -$250.46M | -7.8% |
| Shareholder equity | $26.43M | $17.50M | $37.09M | $65.68M | +51.0% |
| Working capital | $23.49M | $11.45M | $34.37M | $65.64M | +105.2% |
| Net tangible assets | $26.43M | $17.50M | $37.09M | $65.68M | +51.0% |
| Shares issued | 3.22M | 2.06M | 1.57M | 1.43M | +56.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$26.60M | -$40.67M | -$50.73M | -$53.01M | — | +34.6% |
| Depreciation & amortisation | $3.48M | $2.35M | $3.44M | $1.81M | — | +48.1% |
| Stock-based compensation | $4.74M | $6.85M | $8.18M | $9.50M | — | -30.7% |
| Change in working capital | -$3.29M | -$4.92M | -$934.00K | $356.00K | — | +33.1% |
| Operating cash flow | -$21.69M | -$36.33M | -$39.96M | -$41.81M | — | +40.3% |
| Capital expenditure | -$177.00K | -$66.00K | — | -$171.00K | -$913.04K | -168.2% |
| Investing cash flow | $75.00K | $32.00K | $25.00M | -$24.61M | — | +134.4% |
| Financing cash flow | $26.29M | $10.24M | $11.86M | $53.66M | — | +156.7% |
| Free cash flow | -$21.86M | -$36.40M | -$39.96M | -$41.98M | — | +39.9% |
| End cash position | $27.29M | $22.61M | $48.66M | $51.76M | — | +20.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $7.88M | $5.69M | $21.94M | $2.15M | $2.95M | +38.5% |
| Operating revenue | $7.88M | $5.69M | $21.94M | $2.15M | $2.95M | +38.5% |
| Research & development | $49.01M | $6.90M | $16.53M | $4.75M | $7.91M | +610.6% |
| Selling, general & admin | $46.56M | $4.15M | $3.45M | $4.94M | $3.68M | +1,021.5% |
| Total operating expense | $95.57M | $11.05M | $19.98M | $9.69M | $11.59M | +765.0% |
| Operating income | -$87.69M | -$5.36M | $1.96M | -$7.54M | -$8.63M | -1,535.2% |
| Net interest income | $152.00K | $175.00K | $107.00K | $147.00K | $153.00K | -13.1% |
| Pre-tax income | -$153.07M | -$5.18M | $2.08M | -$7.45M | -$8.48M | -2,856.1% |
| Net income | -$153.07M | -$5.18M | $1.58M | -$7.45M | -$8.48M | -2,856.1% |
| Net income to common | -$153.07M | -$5.18M | $1.58M | -$7.45M | -$8.48M | -2,856.1% |
| Basic EPS | -24.14 | -1.08 | 0.30 | -2.10 | -2.70 | -2,135.2% |
| Diluted EPS | -24.14 | -1.08 | 0.30 | -2.10 | -2.70 | -2,135.2% |
| EBIT | -$153.06M | -$5.17M | $2.14M | -$7.37M | -$8.44M | -2,858.3% |
| EBITDA | -$152.65M | -$4.25M | $3.34M | -$6.78M | -$7.64M | -3,496.1% |
| Basic shares | 6.34M | 4.81M | 3.60M | 3.36M | 3.18M | +31.9% |
| Diluted shares | 6.34M | 4.81M | 3.68M | 3.36M | 3.18M | +31.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $17.39M | $16.38M | $27.14M | $11.70M | $27.49M | — | +6.2% |
| Cash & short-term investments | $17.39M | $16.38M | $27.14M | $18.67M | $27.49M | — | +6.2% |
| Accounts receivable | $5.38M | $5.35M | $5.55M | $387.00K | $532.00K | — | +0.5% |
| Total current assets | $26.62M | $26.39M | $36.98M | $25.82M | $30.84M | — | +0.9% |
| Property, plant & equipment | $3.21M | $3.61M | $4.32M | $4.91M | $5.57M | — | -10.9% |
| Total assets | $30.71M | $30.88M | $42.21M | $31.64M | $40.71M | — | -0.6% |
| Total current liabilities | $21.22M | $7.39M | $13.49M | $15.52M | $19.25M | — | +187.1% |
| Current debt | — | — | — | $1.46M | $2.42M | $3.37M | — |
| Total debt | $3.08M | $3.44M | $4.20M | $6.17M | $7.63M | — | -10.6% |
| Total liabilities | $28.40M | $9.27M | $15.78M | $18.40M | $22.55M | — | +206.4% |
| Retained earnings | -$526.71M | -$373.64M | -$368.47M | -$370.05M | -$362.60M | — | -41.0% |
| Shareholder equity | $2.31M | $21.61M | $26.43M | $13.25M | $18.16M | — | -89.3% |
| Working capital | $5.41M | $19.00M | $23.49M | $10.29M | $11.59M | — | -71.6% |
| Net tangible assets | $2.31M | $21.61M | $26.43M | $13.25M | $18.16M | — | -89.3% |
| Shares issued | 5.23M | 3.26M | 3.22M | 2.59M | 2.55M | — | +60.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$153.07M | -$5.18M | $1.58M | -$7.45M | -$8.48M | — | -2,856.1% |
| Depreciation & amortisation | $408.00K | $929.00K | $1.21M | $596.00K | $796.00K | — | -56.1% |
| Stock-based compensation | $23.84M | $48.00K | $610.00K | $1.53M | $1.26M | — | +49,562.5% |
| Change in working capital | $16.63M | -$6.73M | -$4.47M | -$3.62M | $2.97M | — | +347.0% |
| Operating cash flow | -$29.00M | -$10.94M | -$1.08M | -$9.02M | -$3.42M | — | -165.1% |
| Capital expenditure | — | -$121.00K | — | — | -$27.00K | -$150.00K | — |
| Investing cash flow | $0 | -$121.00K | $7.02M | -$6.77M | -$27.00K | — | +100.0% |
| Financing cash flow | $30.02M | $306.00K | $9.49M | $1.00K | $17.80M | — | +9,709.5% |
| Free cash flow | -$29.00M | -$11.06M | -$1.08M | -$9.02M | -$3.44M | — | -162.2% |
| End cash position | $17.55M | $16.53M | $27.29M | $11.85M | $27.64M | — | +6.1% |
Options analytics
Put / call volume
0.09
Call-heavy session
Put / call open interest
0.00
Positioning, not flow
Max pain
0.50
-97.8% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
+50.0%
Puts bid over calls
Call volume
22
Contracts, this expiry
Put volume
2
Contracts, this expiry
Heaviest call OI
0.50
284 contracts
Heaviest put OI
3.00
1 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -1.69 | -24.14 | -1,328.4% |
| Mar 2026 | — | -1.08 | — |
| Dec 2025 | -2.70 | 0.30 | +111.1% |
| Sep 2025 | -2.55 | -2.10 | +17.7% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -2.24 | 3 | $1.03M | -51.9% |
| Next quarter | -1.76 | 3 | $1.00M | -95.4% |
| Current year | -25.01 | 3 | $15.62M | -43.1% |
| Next year | -7.44 | 3 | $8.65M | -44.6% |
Analyst targets & ownership
Mean target$88.00
High target$115.00
Low target$66.00
Implied upside284.45%
Analyst count3
ConsensusSTRONG BUY
Strong buy / Buy0 / 3
Hold0
Sell / Strong sell0 / 0
Held by insiders9.44%
Held by institutions22.80%
Institutions holding60
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
26.43
-13.39% from price
SMA 20
29.16
-21.50% from price
SMA 50
28.25
-18.96% from price
SMA 100
28.11
-18.56% from price
SMA 200
20.28
+12.84% from price
EMA 12
26.37
-13.20% from price
EMA 26
27.85
-17.82% from price
EMA 50
28.20
-18.82% from price
RSI (14)
38.0
Neutral
MACD (12,26,9)
-1.48
Hist -0.96
ATR (14)
4.43
19.34% of price
Realised vol 30D
123.4%
Annualised
Bollinger upper
37.59
20, 2σ
Bollinger lower
20.73
20, 2σ
50 / 200 cross
Golden
28.25 vs 20.28
Trend bias
Above 200
+12.84%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
2.73
More volatile than market
Correlation to SPY
0.18
Largely independent
Realised vol 30D
123.4%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-80.9%
Peak to trough
Max drawdown 5Y
-99.0%
Peak to trough
ATR 14
4.43
19.34% of price
Beta (reported)
2.63
5Y monthly, from filing
Short interest
Shares short
332.11K
Prior 327.44K
Change vs prior
+1.4%
Shorts adding
% of float
4.80%
Normal
% of shares out
4.57%
Against total outstanding
Days to cover
2.1
Liquid
Float
6.85M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 18, 26 | B. Riley Securities | INITIATED | — | Buy |
| Aug 25, 25 | LUCID CAPITAL MARKETS | INITIATED | — | Buy |
| Apr 2, 25 | Citizens Capital Markets | MAINTAINED | Market Outperform | Market Outperform |
| Aug 20, 24 | Stifel | MAINTAINED | Buy | Buy |
| Jul 26, 24 | JMP Securities | MAINTAINED | Market Outperform | Market Outperform |
| Jul 26, 24 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Apr 9, 24 | Stifel | MAINTAINED | Buy | Buy |
| Apr 9, 24 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| Apr 3, 24 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Mar 13, 24 | Jefferies | INITIATED | — | Buy |
| Nov 6, 23 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Jun 15, 23 | Stifel | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split1:30
Split dateApr 24, 2026
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-21
A correspondence can be sent as a document with another submission type or can be sent as a separate submission
CORRESP · 2026-08-18
Periodic Financial Reports
10-Q · 2026-08-14
Offering Registrations
S-3 · 2026-08-12
Corporate Changes & Voting Matters
8-K · 2026-08-03
Additional Forms
D · 2026-07-22
Corporate Changes & Voting Matters
8-K · 2026-07-10
A correspondence can be sent as a document with another submission type or can be sent as a separate submission
CORRESP · 2026-06-29
Headlines
Cue Biopharma’s CUE-221 Hits Phase II Goals, Shows Durable CSU Response
MarketBeat · 9d ago
Cue Biopharma (CUE) Reports Hives Drug Results. Can Longer Relief Set it Apart?
Insider Monkey · 11d ago
An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide
BioPharma Dive · 15d ago
Top Midday Decliners
MT Newswires · 16d ago
Top Premarket Gainers
MT Newswires · 16d ago
Cue Biopharma Shares Jump 41.6% Premarket Following Phase 2 Trial Results
InvestorsHub · 16d ago
Cue Biopharma Meets Primary Goal in a Phase 2 Study of Chronic Hives Disease Drug Candidate
MT Newswires · 16d ago
Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria
GlobeNewswire · 17d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.